Table 1.
Study and sample characteristics
| Assessment | First author | Country | Research Design | Sample Size (n)* |
Histology | HistologyHy HystologyHi | Gender % Women:Men | Age | Language | Administered by | Delivery method | Remote |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Addenbrooke’s Cognitive Examination-revised (ACE-R)59 | Kerrigan 2014 | United Kingdom | Cohort Study | 100 | Radiologically suspected intracranial tumor | Primary Brain Tumor | 50:50 | Categorical | – | Qualified member of the research team | – | – |
| Addenbrooke’s Cognitive Examination (ACE-III)76 | Valiyaveettil 2021 | India | Feasibility Study | 20 | Gliomas | Glioma | 45:55 | Md = 64 | – | – | – | – |
| BCSE (also MoCA and MMSE)60 | Becker 2016 | Germany | Feasibility Study | 58 | Intracranial tumors (Meningioma, Astrocytoma, Glioblastoma multiforme, other, no histopathological report | Primary Brain Tumor | 50:50 | Xd = 58.03 | – | – | – | – |
| Central Nervous System Vital Signs (CNS VS, Dutch Translation)68 | Rijnen 2020 | The Netherlands | Cohort Study | 208 | Glioblastoma | Glioblastoma | 29:71 | X̅ = 58.5 | Dutch | Self-administered | Computer | – |
| CNS Vital Signs (CNS VS, Dutch Translation)65 | van Loenen 2018 | The Netherlands | Cohort Study | 125 | Glioblastoma | Glioblastoma | 33:67 | X̅ = 58.6 | Dutch | Qualified member of the research team | Computer | No |
| Cogstate66 | Cerhan 2019 | United States | Feasibility Study |
39 | Anaplastic astrocytoma, Glioblastoma, Gliosarcoma, Oligodendroglioma | Glioma and Glioblastoma | 37.5:62.5 | Md = 57 | English | Qualified member of the research team | Computer | No |
| FEDA, FEAG58 | Cole 2013 | Germany | Cohort Study | 50 | Brain metastases | Brain Metastases | 56:44 | Md = 56 | German | Self-administered | Paper | Yes |
| Frontal Assessment Battery (FAB)71 | Borde 2021 | India | Cohort Study | 50 | frontal lobe lesions | Frontal lobe lesions | 64:36 | X̅ = 54 | – | – | – | – |
| Macarthur Competence Assessment Tool for Treatment (MacCAT-T)67 | Occhiogrosso 2020 | United States | Feasibility Study | 11 | Grade 3 or 4 Glioma | High-Grade Glioma | 55:45 | Unclear | English | Qualified member of the research team | Verbal | – |
| Milano-Bicocca Battery (MIBIB)70 | Zarino 2020 | Italy | Feasibility Study | 102 | High-Grade Glioma | High-Grade Glioma | 34:66 | Md = 59 | Italian | Qualified member of the research team | – | – |
| MMSE56 | Bae 2011 | United States | Feasibility Study | 143 | Malignant astrocytomas | Low-grade glioma | 35:65 | Categorical | – | Qualified member of the research team | – | – |
| MMSE51 | Choucair 1997 | United States | Feasibility Study | 126 | Low-grade glioma (oligodendroglioma, astrocytoma, oligostrocytoma and other unspecified grade 1–2 glial tumors) | Malignant astrocytomas | 37:63 | Categorical | – | Qualified member of the research team | Paper | No |
| MMSE57 | Yavas 2012 | Turkey | Clinical Trial | 43 | Brain cancer— brain metastases, gbm, pure and mixed naplastic oligodedrogliomas, astrocytoma, lgg (8 separate trials) | primary brain tumor and brain metastases | 44:56 | Md = 53 | – | Self-administered | – | – |
| MoCA61 | Naehrig 2016 | Australia | Cohort Study | 53 | Supratentorial located brain tumor | Brain Metastases | 70:30 | X̅ = 56 | English | – | – | – |
| MoCA54 | Olson 2008 | Canada | Feasibility Study | 40 | recurrant glioblastoma | Recurrant glioblastoma | 45:55 | Md = 60.76 | English | – | – | – |
| MoCA64 | Renovanz 2018 | Germany | Feasibility Study | 63 | High-grade glioma; low-grade glioma; brain metastases (lung; breast; colorectal; melanoma; renal cell; other) | Supratentorial located brain tumor | 40:60 | Md = 62 | German | Qualified member of the research team | – | – |
| MoCA, MMSE, Neuropsychological Battery55 | Olson 2010 | Canada | Feasibility Study | 52 | Brain Metastases | High-grade glioma; low-grade glioma; brain metastases | – | S1 X̅ = 60.7, S2 X̅ = 27.8 | English | – | – | – |
| NeuroCogFX8 | Fliessbach 2010 | Germany | Feasibility Study | 49 | Tumors were grade I (n = 5, 10%), grade II (n = 27, 55%), grade III (n = 15, 31%), and grade IV (n = 2, 4%) gliomas | Glioblastoma | 47:53 | Md = 39 | German | Qualified member of the research team | Computer/ oral | No |
| NeuroCogFX (COG)75 | Tinchon 2021 | Austria | Cohort Study | 18 | Glioblastoma | Primary Brain Tumor | 40:60 | Md = 64 | – | – | Computer | – |
| Neuropsi attention and Memory (second edition)74 | Loaiza 2021 | Colombia | Clinical Trial | 32 | Malignant glioma | Malignant glioma | 44:66 | Md = 46 | Spanish | Neuropsychologist | – | – |
| Neuropsychological Battery73 | Gardner 2021 | United States | Feasibility Study | 119 | High-grade primary brain tumor; Low- grade primary brain tumor; brain metastases; Non-CNS Ca/ NTXCa/NTX | glioblastoma or first recurrence of a locally diagnosed WHO grade II or III glioma | 52:48 | Md = 59 | – | Neuropsychologist | Verbal/ paper via telehealth | Yes |
| Neuropsychological Battery52 | Herman 2003 | United States | Feasibility Study | 30 | Brain Metasteses: Lung (14); breast (7); Melanoma (4); others (5) | Primary brain tumor | 57:43 | Md = 56 | English | Qualified member of the research team | Paper/ physical task | No |
| Neuropsychological Battery & Medical Outcome Study (MOS)72 | Caramanna 2021 | The Netherlands | Clinical trial | 546 | glioblastoma or first recurrence of a locally diagnosed WHO grade II or III glioma | primary brain tumor and brain metastases | 37:63 | X̅ = 55.25 | – | – | – | – |
| Neuropsychological Battery (included MMSE)53 | Regine 2004 | United States | Feasibility Study | 370 | Primary brain tumor | Brain metastases | 45:55 | Categorical | – | Qualified member of the research team | – | – |
| Neuropsychological battery focused on language domains69 | Tibbs 2020 | United States | Clinical trial | 59 | Primary brain tumors and brain metastases | Brain tumor and brain metastases | 43:57 | Md = 47 | English | Neuropsychologist | – | – |
| NIH Health Toolbox Cognitive Battery (NIHTB-CB)63 | Lang 2017 | Canada | Feasibility Study | 18 | Diffuse gliomas (astrocytoma, gbm, oligodendroglioma, pleeomorphic xanthoastrocytoma | Glioma | 28:72 | Md = 39.5 | – | Qualified member of the research team | Computer | – |
| Wechsler Adult Intelligence Scale- Third Edition (WAIS-II) 62 | Gonçalves 2017 | Portugal | Cohort Study | 37 | Brain tumors: glioblastoma, astrocytoma, oligodendroglioma, lymphoma, oligoastrocytoma, meningioma, and glioma | Primary brain tumor | 36:64 | X̅ = 54.90 | Portuguese | Neuropsychologist | – | No |
*Reported as number consented, if consented not provided, reported as number who commenced measure, if not reported, then reported as number who completed measure.